What is Azitra Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Azitra's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.03.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Azitra could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Azitra's Cash-to-Debt or its related term are showing as below:
AZTR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45 Med: 2.03 Max: 8.11
Current: 2.03
During the past 3 years, Azitra's highest Cash to Debt Ratio was 8.11. The lowest was 0.45. And the median was 2.03.
Azitra Cash-to-Debt Historical Data
The historical data trend for Azitra's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Azitra Cash-to-Debt Chart
|
Azitra Annual Data
|
|
Trend |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
8.11 |
0.45 |
2.03 |
|
Azitra Quarterly Data
|
|
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
0.45 |
0.25 |
6.34 |
4.58 |
2.03 |
Competitive Comparison of Azitra's Cash-to-Debt
For the Biotechnology subindustry, Azitra's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azitra's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Azitra's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Azitra's Cash-to-Debt falls into.
Azitra Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Azitra's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Azitra's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azitra (Azitra) Business Description
Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Anitra Inc is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
| Fletcher Aaron G.l. |
10 percent owner |
40 GUEST STREET, BOSTON MA 02135 |
| Leslie W. Kreis |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Andrew Mcclary |
director |
21 BUSINESS PARK DRIVE, BRANFORD CT 06405 |
| Aktiengesellschaft Bayer |
10 percent owner |
BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368 |
| Norm Staskey |
officer: Chief Financial Officer |
21 BUSINESS PARK DRIVE, BRANFORD CT 06405 |
| Bios Azitra Co-invest I, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bayer Us Holding Lp |
10 percent owner |
100 BAYER BOULEVARD, WHIPPANY NJ 07981 |
| Bayer Healthcare Llc |
10 percent owner |
|
| Francisco D. Salva |
director, officer: President and CEO |
4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
| Travis Whitfill |
director, officer: Chief Operating Officer |
C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016 |
| Bios Equity Partners Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii Qp, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii Nt, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Capital Management, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Azitra (Azitra) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AZTR has been successfully added to your